Cambridge, UK, 19 September 2018 – Abzena, plc (AIM: ABZA, Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed an antibody humanisation agreement with Tmunity Therapeutics (Tmunity), a clinical stage T cell therapy company and a leader in the development of new Chimeric Antigen […] Read more

Faron Pharmaceuticals Ltd today announced that it has filed a Clinical Trial Application (CTA) for Clevegen®, an ABZENA Inside product that was originally humanised utilising Abzena’s Composite Human Antibody™ platform. Faron will develop Clevegen®, a novel anti-Clever-1 antibody, for the treatment of selected metastatic or inoperable tumours. It’s great to see an ABZENA Inside product […] Read more

Cambridge, UK, 8 August 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has completed the GMP drug substance manufacture of an ABZENA Inside product that was originally humanised utilising Abzena’s Composite Human Antibody platform™. The product is a novel therapeutic […] Read more

Cambridge, UK, 30 July 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has entered into a master service agreement with one of America’s leading academic medical centres, NYU Langone Health (New York, US). The agreement, for protein engineering and drug […] Read more

Cambridge, UK and Melbourne, Australia, 2 July 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed GMP manufacturing and bioconjugation agreements with Telix Pharmaceuticals Limited (‘Telix’). The agreements have a combined value of $5.9 million and these projects are […] Read more

Cambridge, UK, 29 May 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, will publish its full-year results for the year to 31 March 2018 on Monday, 4 June 2018. A presentation for analysts will be held at 09:30 […] Read more

Cambridge, UK, 26 April 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, is today hosting its first Biopharmaceutical Discovery and Development Symposium and open day, showcasing its new facility at the Babraham Research Campus in Cambridge, UK. The Symposium […] Read more

Cambridge, UK, 16 April 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, today announces its unaudited pre-close update for the year ended 31 March 2018 (‘FY2018’). Following a stronger second half to the year, the Group expects to […] Read more

CAMBRIDGE, England & BRISTOL, PA, USA, Abzena plc, the life sciences group providing services and technologies to enable the design, development and manufacture of biopharmaceutical products, has announced the completion of the facility remodelling for its new antibody-drug conjugate (ADC) GMP manufacturing suite at its Bristol, Pennsylvania site. The facility is being equipped with state-of-the-art […] Read more

Cambridge, UK, 13 March 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the discovery, design, development and manufacture of biopharmaceutical products, has signed an agreement to access a major cell line depository. The agreement with an unnamed institution will allow Abzena access to […] Read more